Related Experiment Videos
Non-stimulant treatments for ADHD.
1Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
European Child & Adolescent Psychiatry
|January 5, 2001
Summary
This review explores non-stimulant medications for Attention Deficit Hyperactivity Disorder (ADHD). Several antidepressants and novel agents show efficacy, but more research is needed for treatments like alpha-2 agonists.
Area of Science:
- Pharmacology
- Neuroscience
- Psychiatry
Background:
- Attention Deficit Hyperactivity Disorder (ADHD) is a complex neurodevelopmental disorder.
- Non-stimulant medications represent an important therapeutic avenue for ADHD management.
- Evaluating the efficacy of non-stimulant ADHD treatments is crucial for clinical practice.
Purpose of the Study:
- To review the existing literature on medication trials for ADHD.
- To assess the scope and efficacy of available non-stimulant treatments for ADHD.
- To identify areas requiring further research in pharmacologic ADHD interventions.
Main Methods:
- Literature review of published medication trials in ADHD.
- Analysis of studies documenting the anti-ADHD activity of various compounds.
- Evaluation of evidence for tricyclic antidepressants, bupropion, tomoxetine, alpha-2 agonists, and cholinergic agents.
Main Results:
- Tricyclic antidepressants demonstrate efficacy in ADHD across over 1,000 subjects.
- Bupropion and tomoxetine are effective non-stimulant treatments for ADHD, supported by controlled trials.
- Limited scientific evidence supports the efficacy of alpha-2 noradrenergic agonists, despite their common use.
- Cholinergic cognitive enhancers show preliminary promise, but require further investigation.
Conclusions:
- Several non-stimulant pharmacologic agents, including certain antidepressants, are effective for ADHD.
- The scientific evidence base for alpha-2 noradrenergic agonists in ADHD is currently limited.
- Further research into novel agents like cholinergic drugs is warranted for ADHD treatment options.